Magnetic resonance imaging plays an increasingly important role in evaluating the effect of cancer treatment. Imaging alone cannot predict pathological complete response and imaging interpretation should be combined with clinical information and endoscopy findings to predict complete response. Professor Blomqvist reviews current and future imaging techniques and whether the quantitative can add significant or important prognostic information over the current qualitative techniques.
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Standardization of imaging to assess treatment response can be linked to a 1976 study by Moertel and Hanley [1] . In that study, 16 oncologists each palpated 12 simulated objects under a foam mattress. The study found that when a 50% reduction in the product of perpendicular diameters is accepted as a response criterion, the objective response rate due to measurement error alone was minimized at 6.8% between different investigators [1] . These data have impacted on the WHO criteria developed in 1977 and the RECIST 1.1 criteria used today when patients with metastatic disease are followed up with cross-sectional imaging in clinical trials.
One of the problems currently faced by multidisciplinary teams is that after chemoradiotherapy (CRT) a tumour can clearly reduce in size, but the amount and location of viable tumour is uncertain. If imaging is performed after CRT, a remaining lesion of fibrotic character is often even present even in cases with a complete pathological response (yPT0N0).
Reasons to assess treatment response 1 
Assessment of treatment complications: if a patient
has not responded to treatment or is getting worse it might be due to a complication, for instance perforation of the tumour. Imaging is performed to assess for complications and to plan surgical management. 2 Assessment of good responders from poor responders: separate those patients who are good responders from those who are poor responders and modify treatment according to response. For example, in a patient with a good response it may be possible to do less extensive surgery such as sphincter preservation in a patient intended initially for an abdominoperineal excision. In a patient with a poor response, modification of neoadjuvant treatment, such as boost radiotherapy to areas where there is poor response, can be considered in a trial setting. 3 Predicting complete response: if imaging can predict pathological complete response (pCR), deferral of surgical management can be considered [2] .
What to assess in MRI after chemoradiation
The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) produced a consensus statement in 2012 detailing the imaging parameters which should be assessed following CRT [3] :
• the distance from the anal verge or anorectal junction and tumour length
• presence/absence of a residual tumour and fibrosis • yT stage and any remaining tumour deposits within the mesorectum
• yN stage and the number of remaining suspicious lymph nodes
• remaining suspicious extramesorectal lymph nodes • persistent involvement/regression from the mesorectal fascia
• the smallest distance (mm) between the remaining tumour and the mesorectal fascia and its location.
Editors' note: the ESGAR guidelines will need updating to reflect the recent advances in knowledge:
Correspondence to: Dr Uday B. Patel, London North-West HealthCare NHS Trust, Northwick Park Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ UK. E-mail: udaypatel2@nhs.net 1 The importance of measuring the depth of extramural spread of tumour rather than distance to the mesorectal fascia. A distance of 1 mm to fascia is the important cut-off to consider but distances > 1 mm hold no prognostic importance [4, 5] and further show worse inter-observer variability and reproducibility than the 1 mm cut-off [6] this has since been updated in the 2017 ESGAR consensus statement [7] . 2 Use of the low rectal staging system to predict risk of pathological circumferential resection margin involvement rather than just the height of the tumour from the anal verge [8] . 3 MRI assessment should include an evaluation of extramural venous invasion on MRI [9, 10] . This has since been added in the updated guidelines [7] .
Techniques to assess tumour response
To date a number of imaging techniques have been investigated as potential biomarkers for tumour response. The techniques which aim to evaluate treatment response are summarized in Table 1 . Whilst tumour volumetry and T2-weighted imaging (mrTRG) have been validated against patient outcomes, many of the other techniques have not undergone validation and therefore remain experimental. Tumour volumetry estimates reduction in mass of the tumour between baseline and after treatment; it has been hypothesized to be a marker of tumour regression as a whole [11] . This can be done by one-dimensional, two-dimensional or three-dimensional measurements.
Assessment of the degree of low signal fibrotic response and intermediate signal residual tumour on T2-weighted imaging forms the basis of the MRI tumour regression grading system [12] .
High signal/restriction on diffusion-weighted imaging corresponds to the cellularity of the tissue and the cell membrane integrity [13] . Injecting contrast and performing sequential dynamic imaging assesses tumour angiogenesis [14] and PET-CT with fluorodeoxyglucose (FDG) assesses changes in tumour metabolism before and after treatment [15] .
Diffusion-weighted imaging
Diffusion-weighted imaging (DWI) is a MR technique in which magnetic field gradients are used to study the microscopic random motions of water protons. Tumour typically appears as areas of restricted/impeded diffusion corresponding to areas of increased cellularity. If images are acquired using two different magnetic gradient strengths, the images acquired can be combined to produce a quantitative measurement, the apparent diffusion coefficient (ADC).
Early experience in using DWI to assess the response of rectal cancer to chemoradiation was published more than 10 years ago. Dzik-Jurasz et al. [16] found a difference in ADC between patients who respond and do not respond to chemoradiation, with a strong negative correlation between mean pretreatment tumour ADC and percentage size change of tumours after chemotherapy (r = À0.67, P = 0.01) and CRT (r = À0.83, P = 0.001).
Combining techniques
After CRT, a decrease in the signal intensity of the entire tumour on T2-weighted images indicates fibrotic change. Measuring two-dimensionally the length and width/ thickness of the tumour in Fig. 1a ,c shows that there has been a significant decrease in volume. Baseline DWI images (Fig. 1b) show high signal/restricted diffusion corresponding to the tumour, and after CRT (Fig. 1d) this high signal restriction of diffusion has obviously decreased. Overall, signal assessment on T2-weighted images, volume and DWI signal change all indicate a good response to CRT. In this case there was histopathological complete response in the resected specimen.
Reviews on MRI for restaging after CRT
Two recent meta-analyses have investigated MRI for restaging rectal cancer after CRT. Both reviews found improved restaging when DWI is performed in addition to T2-weighted MRI. One of the reviews also reported the additional value of fusing multiparameteric MRI along with a conventional protocol [17, 18] . However, it is important to note that the analyses included trials which were not randomized, and multiparametric techniques are still under development and require confirmation, standardization and validation.
Joye et al. [15] recently published a meta-analysis of 14 publications using T2-weighted and diffusion-weighted MRI to predict pCR to CRT in rectal cancer. Pooled analysis of individual patient data showed DWI had a low positive predictive value (PPV) in the prediction of early and late pCR (pooled PPV of 35% and 68%, respectively), while the pooled negative predictive value (NPV) of early and late pCR was 90% [15] . Therefore it has been hypothesized that the major strength of DWI lies in the identification of nonresponders. Similar results were also found on analysis of studies using PET-CT for assessment of response (pooled PPV and NPV of 24% and 86%, respectively, for early pCR and 69% and 96% for late pCR [15] ). In addition, quantitative (ADC) measurement performed less well than visual inspection of the diffusion signal, suggesting that measuring the diffusion on ADC maps alone is not accurate in for the assessment of treatment response in rectal cancer [15] .
Challenges facing imaging
There are a number of challenges faced when using imaging to assess treatment response: these can be broadly categorized into technical limitations and challenges faced due to tumour biology.
On a technical level it is not possible to image to a microscopic level with most of the imaging techniques available, which may limit the assessment of treatment response. In addition, to date there has been very little research regarding the importance of the timing of imaging in relation to the treatment, but experience from studies where surgery has been delayed followed CRT suggests that early biopsy/surgery/assessment of response to treatment may underestimate the true incidence of complete response [19] .
For the future, high-quality image acquisition techniques will require standardization throughout an individual patient's treatment and also within and between centres. Several of the MRI techniques discussed require postprocessing with specific software, which again should be standardized throughout treatment.
Individual tumour biology will also affect the way imaging can assess response to treatment. In terms of histological features it is important to know the histological subtype prior to assessing response to treatment; for example, it is known that the mucinous subtype of rectal tumour responds to treatment differently from nonmucinous tumours [20] ; thus knowledge of tumour histology enables correct evaluation of the treatment effect. In addition the degree of tumour shrinkage is likely to vary between patients and the phenomenon of tumour fragmentation (where the tumour may respond to treatment but shows islands of tumour in its outer border where tumour used to be) will need to be considered. The combination of tumour shrinkage and tumour fragmentation can lead to both under-and overestimation of tumour response by the RECIST criteria, MRI tumour regression grade or the TNM system. 
Techniques under development
Among some research groups there is increasing interest in moving from a qualitative/visual-based imaging evaluation to a quantitative/measurement-based approach.
As discussed, ADC measurements can be undertaken on diffusion-weighted images. Diffusion can be studied in more detail using intravoxel coherent motion [21] , which studies microvascular perfusion without injecting contrast. Magnetization transfer is a different technique which quantifies the degree of fibrotic change with the magnetization transfer ratio.
Other techniques, including 'synthetic MRI', can combine the MR pulse sequences with advanced computer programs to provide automatic quantification data, and 'MR fingerprinting' enables quantification of MR tissue properties. Commercially available software enables measurement of tumour heterogeneity by looking at texture analysis. This technique has been used with both CT and T2-weighted MRI [22] .
Conclusion
MRI plays an increasingly important in evaluating the effect of cancer treatment. Imaging alone cannot predict pCR and imaging interpretation should be combined with clinical information and endoscopy findings to predict pCR.
Future 
Summary of the key points
• Whilst the data regarding the potential of DWI to assess the response to treatment are promising it is not strong enough to make decisions regarding potential surgical resection and/or complete response. DWI needs to be combined with biological and other imaging information.
• DWI is increasingly used, but it is difficult for surgeons to understand the relevance of this technique.
• Other groups are more sceptical about the potential role of DWI and are concerned regarding the quality of the evidence, including sample sizes, research methodology and standardization of the technique.
• To date, data comparing mrTRG (which has been validated against outcomes) with DWI have not been published, but DWI is no longer used in some centres where this comparison has been done [23] .
• Proof of hypothesis that DWI is specific to tumour cellularity is required; this is lacking so far.
• Diffusion is proposed as an additional technique to be used with T2-weighted anatomical imaging where it has been proposed to assist in the differentiation of inflammation, water and fibrosis which may mimic tumour signal.
• There are no data regarding the use of DWI as a biomarker for response to treatment or regarding the potential role of DWI in quantifying the stromal tumour ratio. There is much more data around mrTRG.
• Before DWI/ADC values can be used to alter treatment, understanding of the way ADC values change during treatment is required by examining patients at several time points after treatment. 
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